No Update on Bard Hernia Mesh Settlement Talks Provided, As Deadline For Remand Proposals Loom

Parties are scheduled to submit joint or separate proposals for the remand of cases for trial by June 24, unless they are able to reach a global Bard hernia mesh settlement to resolve large numbers of claims.

When the U.S. District Judge presiding over all federal Bard hernia mesh lawsuits directed the parties to engage in formal mediation, lawyers were directed to notify the Court if they have hit an impasse in negotiations by May 24. However, that date has come and gone without any posted update on the Bard hernia mesh settlement talks, suggesting that the parties have agreed to continuing negotiating leading up to another deadline on June 24.

The negotiations seek to resolve more than 21,000 product liability lawsuits filed against Bard throughout the federal court system, each involving similar allegations that users suffered painful and debilitating injuries caused by design defects associated with various polypropylene products sold in recent years, including the Bard Ventralight, Bard Ventralex, Bard Perfix Plug, Bard 3DMax, and other similar systems.

Since August 2018, the hernia mesh lawsuits have been centralized before U.S. District Judge Edmund A. Sargus in the Southern District of Ohio, as part of a federal Bard hernia mesh multidistrict litigation, or MDL. To date, the parties have already held three early bellwether test trials to help determine how juries may respond to certain evidence and testimony that may be repeated throughout the claims. However, following mixed results, Judge Sargus canceled a planned fourth trial set to begin earlier this year, and ordered the parties to meet with a mediator for Bard hernia mesh settlement talks before he considers returning large numbers of claims to various different U.S. District Courts nationwide for trial.

Hernia Mesh Lawsuits

Did you or a loved one receive a hernia mesh?

Hernia mesh lawsuits are being filed against Bard, Atrium, Covidien and several other hernia mesh manufacturers over mesh failures resulting in injuries and additional surgery.

Learn More See If You Qualify For Compensation

Judge Sargus presided over the first Bard hernia mesh trial in August 2021, which resulted in a defense verdict for Bard. However, a second bellwether trial followed in April 2022, resulting in a $255,000 verdict, and the third resulted in a $500,000 verdict in November 2023.

Although the bellwether trials were designed to promote resolution of the litigation, large numbers of Bard hernia mesh settlements have not materialized, and thousands of individuals are still awaiting their day in court.

Update on Bard Hernia Mesh Lawsuit Negotiations Not Reported

Judge Sargus scheduled a series of Bard hernia mesh lawsuit settlement talks to begin in March, and told the parties and the mediator that they should alert him to any potential impasse in the negotiations by May 24, unless they mutually agreed to extend the deadline.

To date, the court docket shows no signs that either side has filed a report indicating that such an impasse exists. However, another looming deadline requires the parties to submit a joint proposal, or individual proposals, for remanding cases back to different federal courts for trial by June 24, if they are unable to reach a Bard hernia mesh global settlement or plan for resolving large numbers of claims.

The court-ordered mediations were scheduled after the plaintiffs previously asked Judge Sargus to begin remanding Bard hernia mesh lawsuits for trial in December. However, at the time Judge Sargus said that plan was premature.

In January 2024, Judge Sargus indicated that the Court would like to see a three- or four-month period for global Bard hernia mesh settlement talks to be explored before setting the stage for returning cases to various different U.S. District Courts, allowing individual plaintiffs to present their cases before juries to determine the amount of financial compensation they may be entitled to receive.

4 Comments

  • JaquayJuly 24, 2024 at 9:46 am

    I had an umbilical hernia mesh implant surgerical procedure done by Dr. Dominick Eboli of Trenton, New Jersey. In October of 2014. the procedure was done at Capital Health System Regional also in Trenton, New Jersey, And I have been in excruciating pain ever since hance I haven't been able to work since.

  • PeterJuly 8, 2024 at 9:16 pm

    What does the stay on the case indicate?

  • MichaelJune 24, 2024 at 2:41 pm

    The deadline is upon us! What is the plan?

  • JustinJune 5, 2024 at 11:50 pm

    It is very unfortunate that some of us have had less than desirable results with mesh products. I hope that the manufacturers and the attorneys can come to a reasonable agreement that will bring a little bit of joy into those who have suffered and those waiting. Hopefully the new products and surgical techniques will be much more successful

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Master Complaint Outlines Allegations in Ozempic, Wegovy, Mounjaro Lawsuits in MDL
Master Complaint Outlines Allegations in Ozempic, Wegovy, Mounjaro Lawsuits in MDL (Posted 2 days ago)

Plaintiffs pursuing GLP-1 injury lawsuits have filed a Master Complaint outlining common allegations being pursued against Novo Nordisk and Eli Lilly over their diabetes and weight loss drugs, including Ozempic, Wegovy, Mounjaro and others.

Six Years of Depo-Provera Injections Caused Woman To Develop Intracranial Meningioma: Lawsuit
Six Years of Depo-Provera Injections Caused Woman To Develop Intracranial Meningioma: Lawsuit (Posted 3 days ago)

California woman indicates she was unaware there was a link between her meningioma and Depo-Provera injections until a study was published in March 2024, resulting in widespread publicity about the brain tumor risks.